Conversion - Epoetin alfa (Procrit) to Darbepoetin | GrepMed *Z?PkIV/X8$yN7.7 . RETACRIT from multiple-dose vials contains benzyl alcohol and is contraindicated in: For additional details on storage and handling. When adjusting therapy consider hemoglobin rate of rise, rate of decline, ESA responsiveness and hemoglobin variability. Serious allergic reactions to OMONTYS. . epoetin alfa produce similar Hgb levels in patients with CIA. 2007 Aug;23(8):1931-7. doi: 10.1185/030079907X210705. Mircera Dosage Guide - Drugs.com RETACRIT safely and effectively. It is also approved for the reduction of allogeneic red blood cell transfusions in patients undergoing elective, noncardiac, nonvascular surgery. Pussell BA, Walker R; Australian Renal Anaemia Group. Darbepoetin alfa. U qjRO6nY>++xsR _:b*v fzMg918}jS\0^$ i~OG3!tRG`T(b>L&PeRj\L,F#f09w6aCN
$l-FRW+>U0pPhRc/N
R5P-S&C>yxCDL{d^Nij:t5k!_ybecbXharWMmIAS|F7bmM+"qJz)!Yt!V\pz%6aE0oi4ciwy6d" Patients were then switched to fortnightly darbepoetin alfa dosing treatments; the existing weekly dose being doubled and Hb levels fell from 125 to 110 g/L (P < 0.0001), despite an increase in the mean dose from 44.9 to 47.5 microg/week (P = 0.02). This site needs JavaScript to work properly. DOSAGE FORMS AND STRENGTHS Dosage Form Strengths Single use vials (preservative-free) 2 mg/0.5 mL, 3 mg/0.5 mL, 4 mg/0.5 mL, 5 mg/0.5 mL, and 6 mg/0.5 mL, Single use pre-filled syringes (preservative-free) 1 mg/0.5 mL, 2 mg/0.5 mL, 3 mg/0.5 mL, 4 mg/0.5 mL, 5 mg/0.5 mL, and 6 mg/0.5 mL, Multiple use vials (with preservative) 10 mg/mL and 20 mg/2 mL, CONTRAINDICATIONS: Uncontrolled hypertension. in patients with chronic anemia of cancer as well as CIA document
PDF Home Dialysis Programs Standing Orders - Erythropoietin Australian haemodialysis patients on intravenous epoetin alfa or intravenous darbepoetin alfa: how do they compare? k22atr
!h~h[={;X)Sr;:2{+S&x~tlgth6_'N'F?%2 @obXCC patients and 55 darbepoetin alfa patients. Patients with CKD and an insufficient hemoglobin response to ESA therapy may be at even greater risk for cardiovascular reactions and mortality than other patients. Supplied Injection, powder for reconstitution: 5 mg, INDICATIONS AND USAGE Neulasta is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. Splenic Rupture RARE CASES OF SPLENIC RUPTURE HAVE BEEN REPORTED FOLLOWING THE ADMINISTRATION OF NEULASTA. or 100 mcg SC once weekly. gs+"!y]|"bA=!ZuP
xrYB5
EXrL5I'DG(^=9QC4L" VtO!.P/Ndt:U!Vl-6X4&?jv_V'rX:!p[? IV
of the molecule is a more important determinant of potency and receptor
Previous dosage of epoetin alfa: 90,000 units/week, then darbepoetin alfa dosage: 200 mcg/week. The gasping syndrome is characterized by central nervous system depression, metabolic acidosis, and gasping respirations. Use the lowest dose that will maintain a hemoglobin level sufficient to reduce the need for RBC transfusions. x]Y8~w&*qq8g91YJUjUr2$u UuKf"3e&U+Wq&0Y Discontinue Aranesp if responsiveness does not improve. for at least 3 weeks between July 2002 and July 2003. 4y\@:hT4\j
EvZ%fN1gtL|;`,% \ZPrC|.CtI8K,f^f#.PJ#|CZx~igq\jA@PPq. The dose conversion depicted in Table 1 does not accurately estimate the once monthly dose of Aranesp. CONTRAINDICATIONS Neulasta is contraindicated in patients with known hypersensitivity to E coli-derived proteins pegfilgrastim Filgrastim, or any other component of the product. 4. OHSU's formulary erythropoiesis stimulating agent (ESA) is darbepoetin alfa (ARANESP). PDF Highlights of Prescribing Information ------------------dosage and Conversion from Epoetin alfa to Aranesp in patients with CKD on dialysis . Do not dilute. Administer Aranesp once weekly in patients who were receiving epoetin alfa 2 to 3 times weekly. Do not re-enter vial. An official website of the United States government, Recalls, Market Withdrawals and Safety Alerts, FDA approves first epoetin alfa biosimilar for the treatment of anemia, FDA: Office of Hematology and Oncology Products. Billing and Coding: Erythropoiesis Stimulating Agents (ESAs) These adverse reactions included myocardial infarction and stroke, In controlled clinical trials, ESAs increased the risk of death in patients undergoing coronary artery bypass graft surgery (CABG) and the risk of deep venous thrombosis (DVT) in patients undergoing orthopedic procedures, ESAs resulted in decreased locoregional control/progression-free survival (PFS) and/or overall survival (OS). number of patients receiving transfusions, to increase hemoglobin
The dose of MIRCERA , given as a single intravenous or subcutaneous injection, should be based on the total weekly ESA dose at the time of . July/August 2004, Return to
Pull the plunger back to the number on the syringe that matches your dose. Provides access to the latest drug monographs submitted to the Food and Drug Administration (FDA). Evaluate the iron status in all patients before and during treatment. erythropoietin, darbepoetin alfa stimulates erythropoiesis. Platelets produced in response to Neumega were morphologically and functionally normal and possessed a normal life span. group. 1.2 Patients with Acute Myeloid Leukemia Receiving Induction or Consolidation Chemotherapy ZARXIO is indicated for reducing the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (AML) [see Clinical Studies (14.2)]. Retacrit (epoetin alfa-epbx) Biosimilar Formulary Preferred Use Retacrit Aranesp is an erythropoiesis-stimulating agent (ESA) indicated for the treatment of anemia due to: Chronic Kidney Disease (CKD) in patients on dialysis and patients not on dialysis (1.1). The effects of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned Both Retacrit and Procrit are approved for treatment of anemia caused by chronic kidney disease, chemotherapy, use of zidovudine in patients with HIV, and before and after surgery to reduce the chance that red blood cell transfusions will be needed because of blood loss during surgery. Refer to Aranesp package insert for pediatric dosing conversion. Methods: All in-centre haemodialysis patients (n = 60) were converted from an existing subcutaneous epoetin alfa regimen to weekly intravenous darbepoetin alfa. adjustments may be required. similar over the course of therapy for both groups. Conversion from Epoetin alfa to Aranesp in patients with CKD not on dialysis. Call 1-888-4ASSIST to find out more. Questions regarding
Epub 2016 Mar 4. Overall, in
Drug class: Recombinant human erythropoietins. Biological products are generally derived from a living organism and can come from many sources, such as humans, animals, microorganisms or yeast. Both Hb and ferritin concentrations remained within the target range, but darbepoetin dosages fell from 50.8 to 42.3 microg/week by month 3 (P = 0.02). Biosimilar and Reference Products Conversion List for Adults (updated September 2022) Medication Reference Drug or Biosimilar . Accessibility If the hemoglobin level approaches or exceeds 12 g/dL, reduce or interrupt the dose of Aranesp. Update Index. were 9.95 g/dL and 9.80 g/dL in the epoetin alfa- and darbepoetin
Darbepoetin alfa, although several fold more biologically
RETACRIT Dosage and Administration (epoetin alfa-epbx) Correct or exclude other causes of anemia (eg, vitamin deficiency, metabolic or chronic inflammatory conditions, bleeding, etc) before initiating RETACRIT. Careers. PRCA has also been reported in patients receiving ESAs for anemia related to hepatitis C treatment (an indication for which RETACRIT is not approved). Aranesp-treated patients in clinical studies were abdominal pain, edema, and thrombovascular events (6.1). RETACRIT (epoetin alfa-epbx) injection, for i ntravenous or subcutaneous use . 2 0 obj
The majority of patients with CKD will require supplemental iron during the course of ESA therapy. What is the practical conversion dose when changing from epoetin alfa (CIA) for both outpatients and inpatients. This site complies with the HONcode standard for trust- worthy health information: verify here. If hemoglobin increases greater than 1 g/dL in any 2-week period or, If hemoglobin reaches a level needed to avoid RBC transfusion, Withhold dose until hemoglobin approaches a level where RBC transfusions may be required, Reinitiate at a dose 40% below the previous dose, If there is no response as measured by hemoglobin levels or if RBC transfusions are still required after 8 weeks of therapy, Following completion of a chemotherapy course. Background: Please review the latest applicable package insert for additional information and possible updates. Follow the Oncology Center of Excellence on Twitter @FDAOncology. Advise patients to contact their healthcare practitioner for new-onset seizures, premonitory symptoms or change in seizure frequency, For lack or loss of hemoglobin response to RETACRIT, initiate a search for causative factors (eg, iron deficiency, infection, inflammation, bleeding). The U.S. Food and Drug Administration today approved Retacrit (epoetin alfa-epbx) as a biosimilar to Epogen/Procrit (epoetin alfa) for the treatment of anemia caused by chronic kidney disease, chemotherapy, or use of zidovudine in patients with HIV infection. Before endobj
The IV route is recommended for patients on hemodialysis, For adult patients with CKD not on dialysis, The recommended starting dose for adult patients is 50 to 100 Units/kg 3 times weekly IV or SC, The recommended starting dose for pediatric patients (ages 1 month or older) is 50 Units/kg 3 times weekly IV or SC, Recommended dosing for patients with HIV treated with zidovudine, The recommended starting dose in adults is 100 Units/kg as an IV or SC injection 3 times per week, If hemoglobin does not increase after 8 weeks of therapy, increase RETACRIT dose by approximately 50 to 100 Units/kg at 4- to 8-week intervals until hemoglobin reaches a level needed to avoid red blood cell (RBC) transfusions or 300 Units/kg, Recommended starting dose for adults and children undergoing cancer chemotherapy*, 150 Units/kg SC 3 times per week until completion of a chemotherapy course, or, 40,000 Units SC weekly until completion of a chemotherapy course, 600 Units/kg IV weekly until completion of a chemotherapy course. No trial has identified a hemoglobin target level, Aranesp dose, or dosing strategy that does not increase these risks. If a patient or caregiver experiences difficulty measuring the required dose, especially if it is other than the entire contents of the Aranesp prefilled syringe, use of the Aranesp vial may be considered. Cancer patients on chemotherapy (Treatment of patients with erythropoietin levels >200 mU/mL is not recommended). chemotherapy, MDS or MF, continued therapy) Please provide a hemoglobin level (g/dL) for your patient taken within the first 12 weeks of therapy with epoetin and include the date the lab was drawn. alfa and 200 mcg every 2 weeks for darbepoetin alfa. Discontinue RETACRIT therapy immediately if a severe cutaneous reaction, such as SJS/TEN, is suspected, RETACRIT from multiple-dose vials contains benzyl alcohol and is contraindicated for use in neonates, infants, pregnant women, and lactating women. Surgery patients: Prior to initiating treatment, obtain a hemoglobin to establish that is >10 mg/dL or 13 mg/dL: Initial dose: 300 units/kg/day SC x 10 days before surgery, on the day of surgery, and for 4 days after surgery. epoetin alfa and darbepoetin alfa for the management of CIA. To report SUSPECTED ADVERSE REACTIONS, contact Amgen Medical Information at 1-800-77-AMGEN (1-800-772-6436) or . While a discounted alternative to Epogen and Procrit is welcome, there is a catch. transfusions, and iron studies. Efficacy was demonstrated in patients who had experienced severe thrombocytopenia following the previous chemotherapy cycle. GrepMed and the images sourced through this website are NOT a substitute for clinical judgement. Correct or exclude other causes of anemia (e.g., vitamin deficiency, metabolic or chronic inflammatory conditions, bleeding, etc.) Overall, only 10.5% of patients had iron studies before erythropoietin
2007 Apr;12(2):126-9. doi: 10.1111/j.1440-1797.2006.00762.x. Before sharing sensitive information, make sure you're on a federal government site. PDF All Orders Must Be Marked in Ink With a Checkmark to Be Active. - Ohsu Nephrology (Carlton). alfa is as well tolerated and efficacious as epoetin alfa even when
Aranesp is administered less frequently than epoetin alfa. Product Information and Dosing | Mircera Administer Aranesp once every 2 weeks in patients who were receiving epoetin alfa once weekly. Switch from epoetin to darbepoetin alfa in hemodialysis: dose Evaluate response every 4-8 weeks thereafter and adjust the dose accordingly by 50-100 units/kg increments 3 times/week. Epub 2014 Jan 31. The information provided is for educational purposes only. RETACRIT Dosage Forms and Strengths (epoetin alfa-epbx) _
p8"&JjyfEMeRid=D fGKD 8qwR^{c`KNp% Kvu%Q rH]Y "[/|O"1S|FVA@-G%#&DOks]Qf/YQj*$K) Check again for air bubbles. 500 mcg every 3 weeks subcutaneously until completion of a chemotherapy course. 2022Pfizer Inc. All rights reserved. Epogen (epoetin alfa)injection, for intravenous or subcutaneous use Initial U.S.Approval: 1989 WARNING:ESAs INCREASE THE RISK OF DEATH, MYOCARDIAL INFARCTION, STROKE, VENOUS THROMBOEMBOLISM, THROMBOSIS OF VASCULAR ACCESS AND TUMOR PROGRESSION OR RECURRENCE See full prescribing information for complete boxed warning. Disclaimer. Initial U.S. Approval: 2018 . Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. If patient does not respond, a response to higher doses is unlikely. Health care professionals should review the prescribing information in the labeling for detailed information about the approved uses. Depending upon each patient's needs and response, dosage adjustments may be required. Recommended regimens for patients undergoing elective, noncardiac, nonvascular surgery, 300 Units/kg per day SC for 15 days total: administered daily for 10 days before surgery, on the day of surgery, and for 4 days after surgery, 600 Units/kg SC in 4 doses, administered 21, 14, and 7 days before surgery and on the day of surgery. Aranesp (darbepoetin alfa) | Dosing Considerations Non-hematopoietic pathologic changes observed in animals include fibrosis of tendons and joint capsules, periosteal thickening, papilledema, and embryotoxicity. The maximum number of administrations of Aranesp for a billing cycle is 5 times in 30/ 31days. %PDF-1.6
%
*For pediatric patients receiving a weekly epoetin alfa dose of < 1,500 Units/week, the available data are insufficient to determine an Aranesp conversion dose. Patient treatments were converted from subcutaneous epoetin alfa to weekly, intravenous darbepoetin alfa at month 0, at a conversion dose of 200 units epoetin alfa to 1 microg darbepoetin. In controlled trials, patients experienced greater risks for death, serious adverse cardiovascular reactions, and stroke when administered erythropoiesis-stimulating agents (ESAs) to target a hemoglobin level of greater than 11 g/dL. Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. Endogenous G-CSF is a lineage specific colony-stimulating factor which is produced by monocytes fibroblasts, and endothelial cells. 2006 Jan;40(1):58-65; quiz 169-70. doi: 10.1345/aph.1G042. 4 x previous weekly darbepoetin alfa dose (mcg)/0.55. If there are still air bubbles, repeat the steps above to remove them. On May 15, 2018, the Food and Drug Administration approved Retacrit (epoetin alfa-epbx, Hospira Inc., a subsidiary of Pfizer Inc.) as a biosimilar to Epogen/Procrit (epoetin alfa, Amgen Inc.) for . More specifically, 23 patients in the epoetin alfa group
\v0!(?kX }y}3Q6bj>CMOaf&Uhzttxr"m- q! alfa (Aranesp; Amgen) to be therapeutic equivalent products
335 0 obj
<>stream
Aranesp, Epogen, Procrit, and Retacrit are proven and medically necessary to treat anemia associated with myelodysplastic syndromes when the following criteria are met: 2, 3,8,9,32,46 . and 24 patients in the darbepoetin alfa group reached the targeted
1.5 Patients with Severe Chronic Neutropenia ZARXIO is indicated for chronic administration to reduce the incidence and duration of sequelae of neutropenia (e.g. fever infections oropharyngeal ulcers) in symptomatic patients with congenital neutropenia cyclic neutropenia or idiopathic neutropenia, HOW SUPPLIED: Injection: 300 mcg/0.5 mL in a single-use prefilled syringe with BD UltraSafe Passive Needle Guard Injection: 480 mcg/0.8 mL in a single-use prefilled syringe with BD UltraSafe Passive Needle Guard. In some cases, symptoms recurred with rechallenge, suggesting a causal relationship. Epoetin timeline: 2/2020: Switched from Procrit to Retacrit preferred. Study of Transplant Related Anemia Treated With Aranesp (STRATA contracts, darbepoetin alfa is less expensive than epoetin alfa. Northwest Kidney Centers Home Dialysis Programs Standing Orders - Erythropoietin . Table 1. Neumega is not indicated following myeloablative chemotherapy (see package insert for WARNINGS, Increased Toxicity Following Myeloablative Therapy). This has been reported predominantly in patients with CKD receiving ESAs by subcutaneous administration. RETACRIT Instructions For Use (epoetin alfa-epbx) The needle cover of the prefilled syringe contains dry natural rubber (a derivative of latex), which may cause allergic reactions. <>/Filter/FlateDecode/ID[<6A376E50FA41294D8BDE0DC442E05AF8>]/Index[1022 100]/Info 1021 0 R/Length 147/Prev 333934/Root 1023 0 R/Size 1122/Type/XRef/W[1 3 1]>>stream
in two ways: 1) Hgb levels > 12 g/dL or 2) an increase
Additional warnings include high blood pressure, seizures, a condition in which the bone marrow stops making red blood cells thus causing anemia, serious allergic reactions and severe skin reactions. Excessive response: Hemoglobin increases >1 g/dL in any 2-week period: Decrease dose Hemoglobin increases and approaches the target value of 12 g/dL: Decrease weekly dosage by ~25%. Do not shake. It is used in two groups of patients: adults and children with chronic renal failure (long-term, decreasing in the ability of the kidneys to work properly); adults who are receiving chemotherapy for nonmyeloid cancer (cancer not originating in . Neutropenic patients receiving Neulasta who develop fever, lung infiltrates, or respiratory distress should be evaluated for the possibility of ARDS. Costs Associated With Intravenous Darbepoetin Versus Epoetin Therapy in Hemodialysis Patients: A Randomized Controlled Trial. Hgb level. Inadequate response: Hemoglobin increases <1 g/dL over 4 weeks . No difference in conversion dosage could be determined between patients who were epoetin sensitive (<200 units/kg per week) or resistant (>200 units/kg per week, P = NS). Drug class: recombinant human erythropoietins, Aranesp (Darbepoetin Alfa Prefilled Syringes), Anemia Associated with Chronic Renal Failure, If hemoglobin exceeds a level needed to avoid RBC transfusion, If hemoglobin increases by less than 1 g/dL. A 30-day supply of Procrit costs well over $2,000 and prices for Epogen average around $600 per month. Inclusion Criteria: - Subjects who are greater than 6 months post-renal transplant (living or cadaveric) - Using adequate contraceptive precaution, if of childbearing potential - Available for follow-up assessments and dosing visits - Hb concentration less than 11.0 g/dL within 3 months of screening and a hemoglobin concentration less than 11.0 during the screening period Exclusion Criteria . <>/ExtGState<>/XObject<>/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/MediaBox[ 0 0 612 792] /Contents 4 0 R/Group<>/Tabs/S/StructParents 0>>
Administer supplemental iron therapy when serum ferritin is less than 100 mcg/L or when serum transferrin saturation is less than 20%. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances. Unable to load your collection due to an error, Unable to load your delegates due to an error. [Multicenter study of darbepoetin alfa in the treatment of anemia secondary to chronic renal insufficiency on dialysis]. Preclinical trials have shown that mature megakaryocytes which develop during in vivo treatment with Neumega are ultrastructurally normal. before initiating Aranesp. HHS Vulnerability Disclosure, Help 2.25 mcg/kg every week subcutaneously until completion of a chemotherapy course. PDF Erythropoietin Stimulating Agents: Darbepoetin alfa (Aranesp), Epoetin <>stream
Increase dose by 50-100 units/kg 3 times/week if response is not satisfactory in terms of reducing transfusion requirements or increasing hemoglobin after 8 weeks of therapy. Darbepoetin's T1/2 is approximately 3 times that of epoetin alfa. To report an adverse event, please call 1-800-438-1985. Can J Kidney Health Dis. The initial conversion factor of 210 units/microg rose to 275 units/microg (P = 0.01) at month 4. PDF Clinical Policy: Epoetin Alfa (Epogen, Procrit), Epoetin Alfa-epbx lNY0?j/0a6d%J1\3\qdS@*_gy{sl?!H^]ibQ'_(%`lI$5.r U ?Xz:sf;{@(eHB objective of the DUE was to trend usage patterns in the outpatient
Redox Rep. 2016 Jan;21(1):14-23. doi: 10.1179/1351000215Y.0000000022. In addition, Hgb levels were
If hemoglobin continues to increase, hold dose temporarily until hemoglobin begins to decrease, then restart at a dose 25% below the previous dose. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. and transmitted securely. Referrals to independent nonprofitpatient assistance programs. Mechanism of Action: Colony-stimulating factors are glycoproteins which act on hematopoietic cells by binding to specific cell surface receptors and stimulating proliferation differentiation commitment and some end-cell functional activation. Epoetin alfa versus darbepoetin alfa in chemotherapy-related anemia. at the Cleveland Clinic Health System (CCHS) reviewing the use of
In the event that ARDS occurs, Neulasta should be discontinued and/or withheld until resolution of ARDS and patients should receive appropriate medical management for this condition. Note: In patients receiving epoetin alfa 2-3 times per week, darbepoetin alfa is administered once weekly. The site is secure. PenTAG FINAL PROTOCOL 2 darbepoetin alfa (Aranesp [Amgen]). Background: The recommended conversion dose for changing from epoetin alfa to darbepoetin alfa is 200 units to 1 microg. Contributed by. OMONTYS has not been shown to improve symptoms, physical functioning or health-related quality of life. IL-11 has also been shown to have non-hematopoietic activities in animals including the regulation of intestinal epithelium growth (enhanced healing of gastrointestinal lesions), the inhibition of adipogenesis, the induction of acute phase protein synthesis, inhibition of pro-inflammatory cytokine production by macrophages, and the stimulation of osteoclastogenesis and neurogenesis. Retacrit is also approved for use before and after surgery to reduce the chance that red blood cell transfusions will be needed because of blood loss during surgery. !SSe@}vd^W7y% Qf={kGNyHD{9y`S [E^`G,PmN+`R)7oR'=. dbc&@hlv}t``t_/d+)X
T]{oF`S}+c|yt}
}
;X'~'6S;3$]K$t/Z1hrL;\qdHBwtKwHUL`
z0
DY%--V! conversion factor of 1 mcg:220 units Aranesp:EPO. A target
Colony Stimulating Factors - GlobalRPH Do not dilute Aranesp and do not administer in conjunction with other drug solutions. <>
endstream Bone marrow transplantation: 5-10 mcg/kg/day - doses may be increased by 5 mcg/kg according to the duration and severity of neutropenia; recommended steps based on neutrophil response: When ANC >1000/mm3 for 3 consecutive days: Reduce filgrastim dose to 5 mcg/kg/day If ANC remains >1000/mm3 for 3 more consecutive days: Discontinue filgrastim If ANC decreases to <1000/mm3 : Resume at 5 mcg/kg/day If ANC decreases <1000/mm3 during the 5 mcg/kg/day dose, increase filgrastim to 10 mcg/kg/day and follow the above steps. A local search option of this data can be found here. of Pharmacy Drug Information Center (216-444-6456, option #1). Estimated Aranesp Starting Doses (mcg/week) for Patients with CKD on Dialysis Based on Previous Epoetin alfa Dose (Units/week), Previous Weekly Epoetin alfa Dose (Units/week). Each 1 mL single-dose vial of 2,000, 3,000, 4,000, 10,000, and 40,000 Units of epoetin alfa-epbx injection contains 0.5 mg of phenylalanine. Neulasta should not be used for PBPC mobilization.